This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Cam Bioceramics B.v.. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Nol Van De Mortel: Innovator in Biocompatible Compositions
Introduction
Nol Van De Mortel is a notable inventor based in Wassenaar, Netherlands. He has made significant contributions to the field of biocompatible materials, particularly in tissue augmentation. His innovative work has led to the development of a unique patent that addresses the needs of both soft and hard tissue repair.
Latest Patents
Nol Van De Mortel holds a patent for a "Hydroxyapatite tissue filler and its preparation and use." This invention pertains to a biocompatible composition suitable for use in soft or hard tissue augmentation. The composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 µm and an augmentation fraction of ceramic particles of at least 20 µm. The ceramics typically include calcium phosphate. This composition can be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials that are conventionally applied to stabilize augmentation suspensions. He has 1 patent to his name.
Career Highlights
Throughout his career, Nol Van De Mortel has worked with various companies, including Cam Bioceramics B.V. and Access2bone IP B.V. His experience in these organizations has allowed him to refine his expertise in biocompatible materials and their applications in medical fields.
Collaborations
Nol has collaborated with notable professionals in his field, including Klaas De Groot and Nienke De Roode-Beuling. These collaborations have contributed to the advancement of his research and innovations.
Conclusion
Nol Van De Mortel is a distinguished inventor whose work in biocompatible compositions has the potential to significantly impact the medical field. His innovative patent for a hydroxyapatite tissue filler showcases his commitment to advancing tissue augmentation technologies.